US EditionPublished • loading... • Updated
Phase 2 Trial Assesses c-Abl Inhibitor for Early Parkinson’s
Summary by BIOENGINEER.ORG
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Phase 2 Trial Assesses c-Abl Inhibitor for Early Parkinson’s
In a landmark clinical advancement poised to reshape the therapeutic landscape of neurodegenerative disorders, researchers have unveiled compelling data on vodobatinib, a selective c-Abl tyrosine kinase inhibitor, in the treatment of early-stage Parkinson’s disease (PD). This announcement stems from a rigorously designed phase 2, randomized, double-blind, placebo-controlled trial, which marks a pivotal moment in the […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
